Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Fetuin B links vitamin D deficiency and pediatric obesity: Direct negative regulation by vitamin D.

Walker GE, Follenzi A, Bruscaggin V, Manfredi M, Bellone S, Marengo E, Maiuri L, Prodam F, Bona G.

J Steroid Biochem Mol Biol. 2018 Apr 21. pii: S0960-0760(17)30378-3. doi: 10.1016/j.jsbmb.2018.04.009. [Epub ahead of print]

PMID:
29684480
2.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.

J Clin Oncol. 2018 Mar 27:JCO2017765966. doi: 10.1200/JCO.2017.76.5966. [Epub ahead of print]

PMID:
29584549
3.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230-0. doi: 10.1016/j.ygyno.2018.03.050. [Epub ahead of print]

PMID:
29572027
4.

[Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018].

Volpe M, Tocci G, Accettura D, Battistoni A, Bellone S, Bellotti P, Bertolotti M, Borghi C, Casasco M, Consoli A, Coppini R, Corsini A, Costanzo G, Desideri G, Ferri C, Galanti G, Giada F, Icardi G, Lombardi N, Modena MG, Modesti PA, Monti G, Mugelli A, Orsi A, Parati G, Pedretti RF, Perseghin G, Pirro M, Ricotti R, Rizzoni D, Rotella C, Rubattu S, Salvetti G, Sarto P, Tassinari F, Trimarco B, de Kreutzenberg SV, Volpe R.

G Ital Cardiol (Rome). 2018 Feb;19(2 Suppl 1):1S-95S. doi: 10.1714/2874.28988. Italian.

PMID:
29531376
5.

High-normal estimated glomerular filtration rate and hyperuricemia positively correlate with metabolic impairment in pediatric obese patients.

Ricotti R, Genoni G, Giglione E, Monzani A, Nugnes M, Zanetta S, Castagno M, Marolda A, Bellomo G, Bona G, Bellone S, Prodam F.

PLoS One. 2018 Mar 5;13(3):e0193755. doi: 10.1371/journal.pone.0193755. eCollection 2018.

6.

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.

PMID:
29440294
7.

Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

Castagno M, Monzani A, Zanetta S, Genoni G, Giglione E, Ricotti R, Bona G, Prodam F, Bellone S.

J Endocrinol Invest. 2018 Feb 8. doi: 10.1007/s40618-017-0824-6. [Epub ahead of print]

PMID:
29423542
8.

Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.

Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin JA, Rimm DL, Liu Y, Ratner E, Schwartz PE, Santin AD.

Clin Cancer Res. 2018 Jan 19. pii: clincanres.1805.2017. doi: 10.1158/1078-0432.CCR-17-1805. [Epub ahead of print]

PMID:
29351920
9.

Improving clinical diagnosis in SHOX deficiency: the importance of growth velocity.

Genoni G, Monzani A, Castagno M, Ricotti R, Rapa A, Petri A, Babu D, Giordano M, Prodam F, Bona G, Bellone S.

Pediatr Res. 2018 Feb;83(2):438-444. doi: 10.1038/pr.2017.247. Epub 2017 Dec 6.

PMID:
29211059
10.

Compound heterozygosity for two GHR missense mutations in a patient affected by Laron Syndrome: a case report.

Moia S, Tessaris D, Einaudi S, de Sanctis L, Bona G, Bellone S, Prodam F.

Ital J Pediatr. 2017 Oct 12;43(1):94. doi: 10.1186/s13052-017-0411-7.

11.

Insulin resistance, serum uric acid and metabolic syndrome are linked to cardiovascular dysfunction in pediatric obesity.

Genoni G, Menegon V, Secco GG, Sonzini M, Martelli M, Castagno M, Ricotti R, Monzani A, Aronici M, Grossini E, Di Mario C, Bona G, Bellone S, Prodam F.

Int J Cardiol. 2017 Dec 15;249:366-371. doi: 10.1016/j.ijcard.2017.09.031. Epub 2017 Sep 14.

PMID:
28935462
12.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Oct;147(1):145-152. doi: 10.1016/j.ygyno.2017.07.009. Epub 2017 Jul 10.

PMID:
28705408
13.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. doi: 10.1158/1078-0432.CCR-16-2862. Epub 2017 Jul 5.

PMID:
28679774
14.

Genetic variations at the human growth hormone receptor (GHR) gene locus are associated with idiopathic short stature.

Dias C, Giordano M, Frechette R, Bellone S, Polychronakos C, Legault L, Deal CL, Goodyer CG.

J Cell Mol Med. 2017 Nov;21(11):2985-2999. doi: 10.1111/jcmm.13210. Epub 2017 May 29.

15.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jul;146(1):179-186. doi: 10.1016/j.ygyno.2017.04.023. Epub 2017 May 1.

PMID:
28473206
16.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.

Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Med Oncol. 2017 May;34(5):91. doi: 10.1007/s12032-017-0956-8. Epub 2017 Apr 10.

17.

Morphology Quiz: Cytopathology of a thyroid neoplasm.

Nicola M, Onorati M, Bellone S, Collini P, Di Nuovo F.

Cytopathology. 2017 Oct;28(5):438-439. doi: 10.1111/cyt.12416. Epub 2017 Feb 14. No abstract available.

PMID:
28198053
18.

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).

Santin AD, Bellone S, Buza N, Schwartz PE.

Gynecol Oncol Rep. 2016 Dec 14;19:10-12. doi: 10.1016/j.gore.2016.12.003. eCollection 2017 Feb.

19.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.

Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD.

Mol Cancer Ther. 2017 Feb;16(2):323-333. doi: 10.1158/1535-7163.MCT-16-0501. Epub 2016 Dec 12.

20.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26.

21.

Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.

Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W.

J Clin Invest. 2016 Nov 1;126(11):4157-4173. doi: 10.1172/JCI87252. Epub 2016 Oct 10.

22.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

23.

The Association of Bifidobacterium breve BR03 and B632 is Effective to Prevent Colics in Bottle-fed Infants: A Pilot, Controlled, Randomized, and Double-Blind Study.

Giglione E, Prodam F, Bellone S, Monticone S, Beux S, Marolda A, Pagani A, Di Gioia D, Del Piano M, Mogna G, Bona G.

J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S164-S167.

PMID:
27741166
24.

Improved i.p. drug delivery with bioadhesive nanoparticles.

Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11453-11458. Epub 2016 Sep 23.

25.

Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.

Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP.

Clin Cancer Res. 2016 Dec 1;22(23):5682-5687. Epub 2016 Aug 2.

26.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.

Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.

27.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD.

Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.

28.

Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency.

Conca Dioguardi C, Uslu B, Haynes M, Kurus M, Gul M, Miao DQ, De Santis L, Ferrari M, Bellone S, Santin A, Giulivi C, Hoffman G, Usdin K, Johnson J.

Mol Hum Reprod. 2016 Jun;22(6):384-96. doi: 10.1093/molehr/gaw023. Epub 2016 Mar 9.

29.

Influence of Ultraviolet Radiation on the Association between 25-Hydroxy Vitamin D Levels and Cardiovascular Risk Factors in Obesity.

Prodam F, Zanetta S, Ricotti R, Marolda A, Giglione E, Monzani A, Walker GE, Rampone S, Castagno M, Bellone S, Petri A, Aimaretti G, Bona G.

J Pediatr. 2016 Apr;171:83-9.e1. doi: 10.1016/j.jpeds.2015.12.032. Epub 2016 Jan 12.

PMID:
26794470
30.

High Discrepancy in Abdominal Obesity Prevalence According to Different Waist Circumference Cut-Offs and Measurement Methods in Children: Need for Age-Risk-Weighted Standardized Cut-Offs?

Monzani A, Rapa A, Prodam F, Fuiano N, Diddi G, Petri A, Bellone S, Bona G.

PLoS One. 2016 Jan 8;11(1):e0146579. doi: 10.1371/journal.pone.0146579. eCollection 2016.

31.

Primary Effusion Lymphoma: Cytological Diagnosis of a Rare Entity--Report of Two Cases in HIV-Uninfected Patients from a Single Institution.

Nicola M, Onorati M, Bianchi CL, Pepe G, Bellone S, Di Nuovo F.

Acta Cytol. 2015;59(5):425-8. doi: 10.1159/000441938. Epub 2015 Nov 19.

PMID:
26658724
32.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2015 Dec 1;113(11):1641. doi: 10.1038/bjc.2015.388. No abstract available.

33.

Variations in the high-mobility group-A2 gene (HMGA2) are associated with idiopathic short stature.

Fusco I, Babu D, Mellone S, Barizzone N, Prodam F, Fanelli A, Muniswamy R, Petri A, Bellone S, Bona G, Giordano M.

Pediatr Res. 2016 Feb;79(2):258-61. doi: 10.1038/pr.2015.225. Epub 2015 Nov 4.

PMID:
26536448
34.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.

Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

J Exp Clin Cancer Res. 2015 Oct 17;34:123. doi: 10.1186/s13046-015-0241-7.

35.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.

Lopez S, Cocco E, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Terranova C, Angioli R, Santin AD.

Mol Cancer Ther. 2015 Nov;14(11):2519-26. doi: 10.1158/1535-7163.MCT-15-0383. Epub 2015 Sep 2.

36.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.

Black JD, Lopez S, Cocco E, Bellone S, Altwerger G, Schwab CL, English DP, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2015 Sep 29;113(7):1020-6. doi: 10.1038/bjc.2015.306. Epub 2015 Sep 1. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1641.

37.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

Bellone S, Black J, English DP, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Am J Obstet Gynecol. 2016 Jan;214(1):99.e1-8. doi: 10.1016/j.ajog.2015.08.011. Epub 2015 Aug 10.

38.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Schwab CL, English DP, Black J, Bellone S, Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Santin AD.

Gynecol Oncol. 2015 Oct;139(1):112-7. doi: 10.1016/j.ygyno.2015.08.002. Epub 2015 Aug 8.

39.

Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort.

De Rienzo F, Mellone S, Bellone S, Babu D, Fusco I, Prodam F, Petri A, Muniswamy R, De Luca F, Salerno M, Momigliano-Richardi P, Bona G, Giordano M; Italian Study Group on Genetics of CPHD.

Clin Endocrinol (Oxf). 2015 Dec;83(6):849-60. doi: 10.1111/cen.12849. Epub 2015 Aug 6. Review.

PMID:
26147833
40.

Improved survival of patients with hypermutation in uterine serous carcinoma.

Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R.

Gynecol Oncol Rep. 2015 Jan 24;12:3-4. doi: 10.1016/j.gore.2015.01.005. eCollection 2015 Apr.

41.

Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.

Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.

Int J Cancer. 2015 Dec 1;137(11):2618-29. doi: 10.1002/ijc.29632. Epub 2015 Aug 18.

42.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2015 Jul;138(1):11-7. doi: 10.1016/j.ygyno.2015.04.027. Epub 2015 Apr 27.

43.

Adiponectin oligomers are similarly distributed in adequate-for-gestational-age obese children irrespective of feeding in their first year.

Prodam F, Roccio M, Trovato L, Ricotti R, Moia S, Giglione E, Petri A, Walker GE, Bellone S, Bona G.

Pediatr Res. 2015 Jun;77(6):808-13. doi: 10.1038/pr.2015.52. Epub 2015 Mar 11.

PMID:
25760548
44.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Zhu L, Lopez S, Bellone S, Black J, Cocco E, Zigras T, Predolini F, Bonazzoli E, Bussi B, Stuhmer Z, Schwab CL, English DP, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Tumour Biol. 2015 Jul;36(7):5505-13. doi: 10.1007/s13277-015-3218-4. Epub 2015 Feb 11.

45.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD.

Clin Exp Metastasis. 2015 Jan;32(1):29-38. doi: 10.1007/s10585-014-9688-8. Epub 2014 Nov 15.

46.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, Bortolomai I, Bonazzoli E, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Br J Cancer. 2014 Oct 28;111(9):1750-6. doi: 10.1038/bjc.2014.519. Epub 2014 Sep 30.

47.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.

English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer. 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23.

48.

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD.

Gynecol Oncol. 2014 Nov;135(2):312-7. doi: 10.1016/j.ygyno.2014.08.024. Epub 2014 Aug 27.

49.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, Rutherford TJ, Schwartz PE, Santin AD.

Gynecol Oncol. 2014 Oct;135(1):142-8. doi: 10.1016/j.ygyno.2014.08.006. Epub 2014 Aug 12.

PMID:
25124161
50.

Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation.

Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD, Taylor H, Huang Y.

Oncogene. 2015 Jun 4;34(23):3076-84. doi: 10.1038/onc.2014.236. Epub 2014 Aug 4.

PMID:
25088204

Supplemental Content

Loading ...
Support Center